Eli Lilly and Company $LLY Stock Position Decreased by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 48.1% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,103 shares of the company’s stock after selling 12,137 shares during the period. Exchange Traded Concepts LLC’s holdings in Eli Lilly and Company were worth $9,998,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the stock. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company during the 1st quarter valued at approximately $27,000. Sumitomo Mitsui Financial Group Inc. acquired a new position in shares of Eli Lilly and Company during the second quarter valued at $27,000. Evolution Wealth Management Inc. bought a new position in shares of Eli Lilly and Company during the second quarter worth about $29,000. Steph & Co. increased its holdings in shares of Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after acquiring an additional 29 shares during the period. Finally, Financial Gravity Companies Inc. bought a new stake in Eli Lilly and Company in the 2nd quarter valued at about $31,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Zacks raised quarterly and full‑year EPS estimates for LLY, reflecting stronger-than-expected GLP-1 and franchise momentum which supports earnings upside. Zacks raises LLY estimates
• Positive Sentiment: Forbes outlines three possible catalysts that could trigger an LLY rally (pipeline readouts, successful oral GLP‑1 launch execution and M&A/partnerships), providing a roadmap for upside if Lilly executes. 3 Catalysts That Can Start An Eli Lilly Stock Rally
• Positive Sentiment: High‑profile bullish commentary (e.g., Jim Cramer) and positive Phase‑3/clinical data updates (breast cancer, EMBER‑3 imlunestrant results) keep long‑term conviction intact for growth beyond obesity drugs. Jim Cramer on Lilly
• Positive Sentiment: Broker support remains: Bank of America and others maintain Buy/overweight views and some firms have raised price targets based on eventual realization of obesity‑drug earnings. This provides analyst backing for potential rebounds. BofA maintains Buy on Eli Lilly
• Neutral Sentiment: Sector rotation into healthcare/XLV increases passive demand for LLY (it’s a large ETF holding), supporting structural investor interest even amid short‑term volatility. Sector Rotation: 2 Smart Money Moves for 2026
• Neutral Sentiment: Deal speculation (reported meetings with Abivax/French officials) and ongoing partnership chatter could be upside optionality but are early-stage and uncertain. Abivax soars on Lilly meeting report
• Negative Sentiment: Major near-term headwind: the FDA approved Novo Nordisk’s oral Wegovy pill — the first daily oral obesity drug — giving Novo a first‑mover advantage that could pressure Lilly’s orforglipron launch timing/market share and is driving the stock pullback. Novo Nordisk weight-loss drug wins US approval as a daily pill
• Negative Sentiment: Market reaction and commentary: multiple outlets report LLY shares falling as investors re‑price competitive risk and potential slower or lower peak sales for Lilly’s oral GLP‑1; near‑term investor focus will be on comparative efficacy, launch execution, and pricing dynamics. Eli Lilly Stock Falls. Novo Nordisk Got a Wegovy Weight-Loss Pill Approved in U.S.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $1,070.80 on Wednesday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The business’s 50-day moving average price is $971.08 and its 200 day moving average price is $835.68. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,111.99. The firm has a market cap of $1.01 trillion, a P/E ratio of 52.39, a PEG ratio of 1.09 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Wall Street Analysts Forecast Growth

LLY has been the topic of several analyst reports. BMO Capital Markets set a $1,200.00 price target on shares of Eli Lilly and Company in a research note on Thursday, December 4th. National Bankshares set a $1,286.00 target price on Eli Lilly and Company in a research report on Monday, December 1st. Daiwa Capital Markets set a $1,230.00 price target on Eli Lilly and Company and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Daiwa America raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 16th. Finally, HSBC reaffirmed a “hold” rating and issued a $1,070.00 price objective on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $1,155.36.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.